Preparation process of biodegradable embolism microspheres with blood coagulation function

Through the preparation of sodium alginate-based gel microspheres, combined with microfluidic control technology and drug load, the problem of insufficient coagulation effect of alginate microspheres is solved, rapid coagulation and long-term sustained release are achieved, and non-alcoholic ventricular septum is improved. Effects of ablation therapy.

CN118949114APending Publication Date: 2024-11-15HUNAN UNIV OF TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411169713.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-25
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing alginate microspheres are insufficient in the process of cardiovascular blockage, and the thrombin is unstable, making it difficult to meet the needs of non-alcoholic ventricular septal ablation agents. A microsphere that can quickly achieve coagulation and has long-term sustained release is needed. Preparation method.

Method used

Sodium alginate-based gel microspheres are used to prepare microspheres with good compression resistance and resilience through microfluidic control technology, combining thrombin and water-soluble bialdehyde polysaccharides, adjusting pH value and adding lecithin to form an oil phase Aqueous microspheres were then sprayed with rapamycin complex solution to achieve drug loading and sustained release.

Benefits of technology

The rapid release of coagulation drugs in a short period of time and continuous release in a long period of time has been achieved, which has improved the treatment effect of hypertrophic cardiomyopathy, enhanced the strength and stability of the microspheres, and ensured the sustainability of the coagulation effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949114A_ABST
    Figure CN118949114A_ABST
Patent Text Reader

Abstract

The invention discloses a biodegradable embolism microsphere with a blood coagulation function, which is prepared by the following steps: by taking sodium alginate, water-soluble protein, thrombin and a water-soluble dialdehyde polysaccharide aqueous solution as a water phase and taking low-viscosity oil mixed phospholipid as an oil phase, balling through a microfluidic technology, putting the balled product into a collected liquid dissolved with calcium chloride, slowly stirring for 1-2 hours, filtering, washing and drying to obtain the biodegradable embolism microsphere with the blood coagulation function. Taking out, washing and purifying for multiple times, spraying a rapamycin solution on the surface through an atomization spraying device to realize surface drug loading, and storing in normal saline. The microspheres can achieve the effects of rapid blood coagulation and continuous blood coagulation after embolism, can provide the anti-immune effect through surface rapamycin, and can be used as an embolism agent to be applied to the field of interventional therapy of hypertrophic cardiomyopathy and other diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to gel embolic microspheres and a preparation method thereof, and in particular to gel embolic microspheres which have excellent mechanical properties, stable morphology, can rapidly achieve blood coagulation, can load blood coagulation drugs and achieve sustained release, and a preparation method thereof. Background Art

[0002] Hypertrophic cardiomyopathy is one of the main causes of sudden cardiac death. For patients with poor drug control, percutaneous septal myocardial ablation (ASA) has gradually become an alternative treatment to surgery. However, the anhydrous alcohol ablation agent currently used is uncontrollable after being injected into the target blood vessel, and often leaks or flows into other coronary arteries, leading to serious consequences such as myocardial infarction or conduction system damage in non-target ablation sites. Therefore, anhydrous alcohol is not an ideal ASA ablation agent.

[0003] In recent years, non-alcoholic septal ablation has become a research hotspot in the field of interventional treatment of hypertrophic obstructive cardiomyopathy (HOCM). Currently, there have been single-center, small-sample studies using microcoils, gelatin sponges or polymer particles, cyanoacrylate adhesives and other media for physical or chemical ablation. The conclusions are generally believed to have good perioperative safety, but whether the above media can achieve the same effectiveness as alcohol ablation needs further verification. The use of natural polymer biomaterials to prepare microsphere ablative or embolic agents has been one of the hot topics in interventional material research in recent years.

[0004] In the field of cardiovascular research, various forms of alginate hydrogels have been used in myocardial cell regeneration tissue engineering, growth factor delivery, and intracoronary injection to increase the mechanical stability of the infarct site. The alginate hydrogels formed with divalent or trivalent metal cations have a similar structure to the extracellular matrix. The most studied one is the alginate and Ca 2+ The calcium alginate microspheres formed can be transported in vivo by Ca 2+ -Na +Ion exchange hydrolyzes and eventually forms water-soluble sodium alginate molecules with a molecular weight of less than 50kDa, which can be excreted from the body through the kidneys, with good biocompatibility, safety and non-toxicity. In addition, sodium alginate can be prepared into alginate microspheres with characteristics such as controllable degradation and drug loading by special processes. However, as an ablative agent, alginate microspheres mainly block blood flow by gradually filling from the distal end to the proximal end of the blood vessel during the process of blocking blood vessels, and the coagulation effect is obviously insufficient. Therefore, pure alginate microspheres are not an ideal non-alcoholic ventricular septal ablative agent. The use of coagulation drugs such as thrombin alone also has problems. Thrombin itself is unstable and is easily inactivated when it encounters acid, alkali, heavy metals or high temperature. If special microspheres can be effectively loaded, the combined effect of the two will be effectively exerted. But at the same time, the ideal embolic agent should also meet other series of conditions, such as excellent strength and embolic properties, can achieve coagulation effect in the short term and cooperate with long-term mechanism, can produce degradation while also ensuring the coagulation effect, etc.

[0005] In view of the above problems, the present invention develops a new type of drug-loaded sodium alginate-based gel embolic microspheres, which can not only meet the basic performance requirements, but also achieve a combination of short-term large-scale burst release of drugs and long-acting release of drugs, which will greatly improve the therapeutic effect of HOCM. Summary of the invention

[0006] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a sodium alginate-based microsphere, which has good compression resistance and resilience, stable shape, can quickly release coagulation drugs during embolism, and can continuously release coagulation drugs to ensure the effect.

[0007] The microspheres are made by the following technologies: A biodegradable embolic microsphere with coagulation function, the preparation process of which is as follows: a: dissolving a certain amount of sodium alginate, water-soluble protein, thrombin, and water-soluble dialdehyde polysaccharide macromolecules in water to prepare an aqueous phase prepolymer solution; b: Using low viscosity oil mixed with lecithin as the oil phase; c: before adding to the microfluidics, the pH value of the aqueous prepolymer solution is adjusted to between 5 and 6.5 using a weak acid; d: The microspheres are obtained by outputting through microfluidic technology, and the flow rates of the water phase and the oil phase are controlled to control the size of the spheres; the outflowing microspheres are collected with a calcium chloride aqueous solution as a collecting liquid, and a weak alkaline solution is added to adjust the microsphere collecting liquid to neutrality, and the collecting liquid is continuously stirred at 100-200 rpm for 1-2 hours; f: After filtering out the microspheres, spraying the rapamycin composite aqueous solution on the surface of the microspheres with a nano-scale atomization spray device; g: After spraying, place the microspheres in physiological saline and store at 0-4°C.

[0008] Furthermore, the mass concentration of sodium alginate in the aqueous prepolymer solution is between 3-6%, the mass concentration of water-soluble dialdehyde polysaccharide macromolecules is between 2-4.5%, and the volume concentration of thrombin is between 30-60 mg / ml.

[0009] Furthermore, the mass concentration of the collected calcium chloride aqueous solution is between 2-4%.

[0010] Furthermore, the low-viscosity oil is one of ethyl acetate, hexane, liquid paraffin, and dimethyl silicone oil. After adding lecithin, the mixture is shaken for 5-10 minutes using an ultrasonic oscillation device to achieve homogenization; preferably, the viscosity of the oil is between 0.2 and 200 cSt.

[0011] Furthermore, the mass concentration of lecithin mixed in the oil is between 2-4%.

[0012] Furthermore, the phospholipid includes one of refined egg yolk lecithin, refined soybean lecithin, and distearoyl lecithin, and the lecithin has a hydrophilic end and a hydrophobic end, which can realize the connection of hydrophilic-lipophilic molecules. Preferably, Lipoid E80 type refined lecithin can be selected.

[0013] Furthermore, the water-soluble protein is a water-soluble protein containing an amino group, including one of polyaspartic acid, polyglutamic acid, and ε-polylysine.

[0014] Furthermore, the rapamycin composite solution uses 10% by mass DMSO / water solution as solvent, in which rapamycin, a surfactant and mannitol are dissolved, wherein the concentration of rapamycin is between 1-4 mg / ml, the mass concentration of the surfactant is between 1-2%, and the mass concentration of mannitol is between 0.01-0.03%.

[0015] Furthermore, mannitol and rapamycin were used together to reduce edema in the early stage of embolization.

[0016] Furthermore, the flow rate of the oil phase is 20-80 μL / min, and the flow rate of the water phase is 2-8 μL / min; preferably, the flow rate of the oil phase is 40-80 μL / min, and the flow rate of the water phase is 2-4 μL / min.

[0017] Furthermore, the water-soluble dialdehyde polysaccharide macromolecule is a polysaccharide with a dialdehyde structure, including one of starch, sodium alginate, xanthan gum, pullulan, dextran, chitosan, and carrageenan, and the molecular weight is between 1000-8000.

[0018] Furthermore, water-soluble dialdehyde polysaccharide macromolecules can be directly purchased from the market, or can be obtained by oxidizing the polysaccharide; for example, by oxidizing with sodium periodate or potassium permanganate.

[0019] Furthermore, the weak acid may be any one of hydrochloric acid, oxalic acid and formic acid.

[0020] Furthermore, the weak base can be any one of sodium hydroxide, potassium hydroxide and ammonia water.

[0021] Furthermore, the amine and aldehyde groups of the substances in the aqueous phase undergo a Schiff base reaction under weakly acidic conditions to cause cross-linking; acidity and temperature can be used to control the reaction rate to ensure that the aqueous solution flows smoothly out of the microfluidic chip.

[0022] Furthermore, the particle size that can be prepared is between 50-800μm, and different models can be set according to the particle size: 50-100μm, 80-120μm, 120-160μm, 140-220μm, 200-280μm, 260-340μm, 320-420μm, 400-500μm, 500-600μm, 600-700μm, 700-800μm.

[0023] Furthermore, the nano-scale atomization spraying device sprays the rapamycin composite solution on the microspheres, and the thickness of the surface drug layer formed after spraying is between 10-40nm.

[0024] Furthermore, the rapamycin can achieve transfer to the embolized blood vessels within 2 hours of embolization.

[0025] Furthermore, the microspheres begin to degrade between 16 and 24 days under vascular physiological conditions.

[0026] Furthermore, the microspheres maintain a good thrombin sustained-release effect before starting to degrade, and after starting to degrade, the drug begins to release in a secondary burst.

[0027] Furthermore, the microspheres swell in equilibrium in physiological saline, and the ratio of their volume to the volume when flowing out of the microfluidics is between 1.1-1.4.

[0028] Furthermore, the microspheres can withstand a compression deformation between 50-85%. If the compression deformation exceeds the limit, the microspheres cannot recover their shape. Within the compression limit, the microspheres can recover their shape.

[0029] Furthermore, the microspheres of the present invention have multiple advantages: Combined with microfluidics technology, a large amount of coagulation drugs can be packaged to improve the treatment effect; The microsphere shell has excellent strength and resilience, and the final swelling is moderate, which can ensure a good embolization effect; In situ microsphere surface modification was achieved through the addition of special binding phospholipids into the oil phase; Rapamycin is loaded with lipids by binding to phospholipids on the surface of microspheres, and can be rapidly released after embolization, thereby rapidly promoting coagulation and improving anti-immunity. It can achieve long-acting sustained release, which can reach 16-24 days of sustained release. After the embolic agent begins to gradually degrade, it can also achieve a burst release of the drug to enhance the therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 This is the appearance of the drug-loaded embolic microspheres prepared in Example 1; Figure 2 This is the in vitro release graph of thrombin from the drug-loaded embolism prepared in Example 1; Figure 3 This is the in vitro release graph of thrombin from the drug-loaded embolism prepared in Example 2; Figure 4 This is the in vitro release graph of thrombin from the drug-loaded embolism prepared in Example 3; Figure 5 This is the in vitro release graph of thrombin from the drug-loaded embolus prepared in Example 4. DETAILED DESCRIPTION

[0031] The embodiments of the present application will be described in detail below in conjunction with examples, but those skilled in the art will understand that the following examples are only used to illustrate the present application and should not be construed as limiting the scope of the present application. Example 1

[0032] A biodegradable embolic microsphere with coagulation function, the preparation process of which is as follows: a: dissolving a certain amount of sodium alginate, polyaspartic acid, thrombin, and water-soluble dialdehyde chitosan in water to prepare an aqueous prepolymer solution; b: Dimethyl silicone oil mixed with Lipoid E80 type refined lecithin as the oil phase; c: The pH value of the aqueous prepolymer solution was adjusted to 6.5 by oxalic acid before adding to the microfluidics; d: The flow rate of the oil phase was set to 60 μL / min, and the flow rate of the water phase was set to 3 μL / min, and the microspheres were obtained by flowing out; the microspheres were collected with a 3.5% calcium chloride aqueous solution as the collection liquid, and NaOH solution was added to adjust the microsphere collection liquid to neutrality, and the collection liquid was continuously stirred at 150 rpm for 1.5 hours; e: After filtering out the microspheres, spraying the rapamycin composite aqueous solution on the surface of the microspheres with a nano-scale atomization spray device; f: After spraying, place the microspheres in physiological saline and store at 2°C.

[0033] The mass concentration of sodium alginate in the aqueous prepolymer solution is 4%, the mass concentration of water-soluble dialdehyde chitosan is 3.2%, the volume concentration of thrombin is 50 mg / ml, and the mass concentration of the calcium chloride aqueous solution in the collection solution is 3%.

[0034] The viscosity of the dimethyl silicone oil is 160 cSt, and the mass concentration of Lipoid E80 type refined lecithin in the oil is 3%.

[0035] After the lecithin is added to the oil phase solution, an ultrasonic device is used to ultrasonicate for 30 minutes to promote uniform dispersion of the phospholipids in the oil phase.

[0036] The molecular weight of the water-soluble dialdehyde chitosan is 4600.

[0037] The rapamycin composite solution uses 10% by mass DMSO / water solution as solvent, and contains rapamycin, Span 80 and mannitol, wherein the concentration of rapamycin is 2.5 mg / ml, the mass concentration of Span 80 is 1.6%, and the mass concentration of mannitol is 0.002%.

[0038] The prepared microspheres have a particle size of 140-220 μm and an appearance of Figure 1 shown.

[0039] The thickness of the rapamycin on the surface of the microsphere is 25 nm, and the rapamycin can be transferred to the embolized blood vessels within 2 hours of embolization.

[0040] The microspheres began to degrade significantly under vascular physiological conditions at 18 days, and the microspheres began to deform.

[0041] The microspheres maintained a good thrombin sustained release effect before starting to degrade, and the in vitro release curve was as follows: Figure 2 shown.

[0042] The ratio of the equilibrium swelling volume of the microspheres in physiological saline to the volume when flowing out of the microfluidics is 1.25.

[0043] The microspheres can withstand a compression deformation of 70%.

[0044] Example 2 A biodegradable embolic microsphere with coagulation function, the preparation process of which is as follows: a: dissolving a certain amount of sodium alginate, polyglutamic acid, thrombin and water-soluble dialdehyde starch in water to prepare an aqueous prepolymer solution; b: Hexane mixed with ultrafine German Cargill soybean lecithin as the oil phase; c: The pH value of the aqueous prepolymer solution was adjusted to 5.8 by oxalic acid before adding to the microfluidics; d: The flow rate of the oil phase was set to 65 μL / min, and the flow rate of the water phase was set to 3.5 μL / min, and the microspheres were obtained by flowing out; the microspheres were collected with calcium chloride aqueous solution as the collection liquid, and NaOH solution was added to adjust the microsphere collection liquid to neutrality, and the collection liquid was continuously stirred at 180 rpm for 1.5 hours; e: After filtering out the microspheres, spraying the rapamycin composite aqueous solution on the surface of the microspheres with a nano-scale atomization spray device; f: After spraying, place the microspheres in physiological saline and store at 1°C.

[0045] The mass concentration of sodium alginate in the aqueous prepolymer solution is 3.5%, the mass concentration of water-soluble dialdehyde chitosan is 4%, the volume concentration of thrombin is 45 mg / ml, and the mass concentration of the calcium chloride aqueous solution in the collection solution is 3.5%.

[0046] The viscosity of the hexane is 60 cSt, and the mass concentration of soybean lecithin in the hexane is 3.5%.

[0047] After the lecithin is added to the oil phase solution, an ultrasonic device is used to ultrasonicate for 30 minutes to promote uniform dispersion of the phospholipids in the oil phase.

[0048] The molecular weight of the dialdehyde starch is 3200.

[0049] The rapamycin composite solution uses 10% by mass DMSO / water solution as solvent, and contains rapamycin, Span 80 and mannitol, wherein the concentration of rapamycin is 3.2 mg / ml, the mass concentration of Span 80 is 1.3%, and the mass concentration of mannitol is 0.015%.

[0050] The particle size of the prepared microspheres is 80-120 μm.

[0051] The thickness of the rapamycin on the surface of the microsphere is 25 nm, and the rapamycin can be transferred to the embolized blood vessels within 2 hours of embolization.

[0052] The microspheres began to degrade significantly under vascular physiological conditions at 21 days, and the microspheres began to deform.

[0053] The microspheres maintained a good thrombin sustained release effect before starting to degrade, and the in vitro release curve was as follows: Figure 3 shown.

[0054] The ratio of the equilibrium swelling volume of the microspheres in physiological saline to the volume when flowing out in the microfluidics is 1.2.

[0055] The microspheres can withstand a compression deformation of 65%.

[0056] Example 3 A biodegradable embolic microsphere with coagulation function, the preparation process of which is as follows: a: dissolving a certain amount of sodium alginate, ε-polylysine, thrombin, and water-soluble dialdehyde glucose in water to prepare an aqueous phase prepolymer solution; b: Hexane mixed with distearoyl lecithin as the oil phase; c: The pH value of the aqueous prepolymer solution was adjusted to 6.2 by oxalic acid before adding to the microfluidics; d: The flow rate of the oil phase was set to 45 μL / min, and the flow rate of the water phase was set to 2 μL / min, and the microspheres were obtained by flowing out; the microspheres were collected with calcium chloride aqueous solution as the collecting liquid, and the microsphere collecting liquid was adjusted to neutral by adding NaOH solution, and the collecting liquid was continuously stirred at 120 rpm for 1.5 hours; e: After filtering out the microspheres, spraying the rapamycin composite aqueous solution on the surface of the microspheres with a nano-scale atomization spray device; f: After spraying, place the microspheres in physiological saline and store at 2°C.

[0057] The mass concentration of sodium alginate in the aqueous phase prepolymer solution is 4.2%, the mass concentration of water-soluble dialdehyde glucose is 2.8%, the volume concentration of thrombin is 50 mg / ml, and the mass concentration of the calcium chloride aqueous solution of the collection solution is 3%.

[0058] The viscosity of the ethyl acetate is 0.4 cSt, and the mass concentration of distearoyl lecithin in hexane is 3.5%.

[0059] After the lecithin is added to the oil phase solution, an ultrasonic device is used to ultrasonicate for 30 minutes to promote uniform dispersion of the phospholipids in the oil phase.

[0060] The molecular weight of the dialdehyde glucose is 1800.

[0061] The rapamycin composite solution uses 10% by mass DMSO / water solution as solvent, and contains rapamycin, Tween 20 and mannitol, wherein the concentration of rapamycin is 2.8 mg / ml, the mass concentration of Span 80 is 1.6%, and the mass concentration of mannitol is 0.018%.

[0062] The particle size of the prepared microspheres is 500-600 μm.

[0063] The thickness of the rapamycin on the surface of the microsphere is 32 nm, and the rapamycin can be transferred to the embolized blood vessels within 2 hours of embolization.

[0064] The microspheres began to degrade significantly under vascular physiological conditions at 22 days, and the microspheres began to deform.

[0065] The microspheres maintained a good thrombin sustained release effect before starting to degrade, and the in vitro release curve was as follows: Figure 4 shown.

[0066] The ratio of the equilibrium swelling volume of the microspheres in physiological saline to the volume when flowing out in the microfluidics is 1.28.

[0067] The microspheres can withstand a compression deformation of 60%.

[0068] Example 4 A biodegradable embolic microsphere with coagulation function, the preparation process of which is as follows: a: dissolving a certain amount of sodium alginate, polyaspartic acid, thrombin, and water-soluble dialdehyde sodium alginate in water to prepare an aqueous phase prepolymer solution; b: Liquid paraffin mixed with Lipoid E80 type refined lecithin as the oil phase; c: The pH value of the aqueous prepolymer solution was adjusted to 6.0 by hydrochloric acid before adding to the microfluidics; d: The flow rate of the oil phase was set to 65 μL / min, and the flow rate of the water phase was set to 6 μL / min, and the microspheres were obtained by flowing out; the microspheres were collected with calcium chloride aqueous solution as the collection liquid, and NaOH solution was added to adjust the microsphere collection liquid to neutrality, and the collection liquid was stirred at 150 rpm for 2 hours; e: After filtering out the microspheres, spraying the rapamycin composite aqueous solution on the surface of the microspheres with a nano-scale atomization spray device; f: After spraying, place the microspheres in physiological saline and store at 1°C.

[0069] The mass concentration of sodium alginate in the aqueous phase prepolymer solution is 5%, the mass concentration of water-soluble dialdehyde sodium alginate is 3.6%, the volume concentration of thrombin is 52 mg / ml, and the mass concentration of the calcium chloride aqueous solution of the collection solution is 2.8%.

[0070] The viscosity of the liquid paraffin is 420 cSt, and the mass concentration of Lipoid E80 type refined lecithin in the liquid paraffin is 3.8%.

[0071] After the lecithin is added to the liquid paraffin, an ultrasonic device is used to ultrasonicate for 50 minutes to promote uniform dispersion of the phospholipids in the oil phase.

[0072] The molecular weight of the dialdehyde sodium alginate is 3500.

[0073] The rapamycin composite solution uses 10% by mass DMSO / water solution as solvent and contains rapamycin, Tween 80 and mannitol, wherein the concentration of rapamycin is 3.6 mg / ml, the mass concentration of Tween 80 is 15%, and the mass concentration of mannitol is 0.014%.

[0074] The particle size of the prepared microspheres is 50-100 μm.

[0075] The thickness of the rapamycin on the surface of the microsphere is 36 nm, and the rapamycin can be transferred to the embolized blood vessels within 2 hours of embolization.

[0076] The microspheres began to significantly degrade under vascular physiological conditions at 24 days, and the microspheres began to deform.

[0077] The microspheres maintained a good thrombin sustained release effect before starting to degrade, and the in vitro release curve was as follows: Figure 5 shown.

[0078] The ratio of the equilibrium swelling volume of the microspheres in physiological saline to the volume when flowing out in the microfluidics is 1.31.

[0079] The microspheres can withstand a compression deformation of 78%.

[0080] Comparative Example 1 Comparative Example 1 is based on Example 1, and the flow rates of the water phase and the oil phase are adjusted to 40 μL / min for the oil phase and 8 μL / min for the water phase, and the particle size of the microspheres obtained is between 160-200 μm.

[0081] The volume ratio of the prepared microspheres in equilibrium swelling volume in physiological saline to the volume when flowing out in microfluidics was 1.36.

[0082] The prepared microspheres can withstand a compression deformation of 80%.

[0083] The drug release rate of the prepared microspheres was faster than that of Example 1 in the initial stage.

[0084] Comparative Example 2 Comparative Example 2 is based on Example 1, except that Lipoid E80 type refined lecithin is not added to the oil phase.

[0085] After the prepared microspheres were sprayed with the rapamycin composite aqueous solution, rapamycin could not form a continuous phase on the surface of the microspheres, and very little drug was adsorbed on the surface.

[0086] Other properties are basically similar to those of Example 1.

[0087] Comparative Example 3 Comparative Example 3 is compared with Example 1. In the preparation process a, polyaspartic acid is not added, and the other processes are completely the same.

[0088] The particle size of the prepared microspheres is 160-280 μm.

[0089] After the prepared microspheres were sprayed with the rapamycin composite aqueous solution, rapamycin did not form a continuous phase on the surface of the microspheres, and the surface thickness of the drug was about 10 nm, indicating that the rapamycin loading effect was poor.

[0090] The prepared microspheres began to degrade significantly under vascular physiological conditions at 16 days, and the microspheres began to deform.

[0091] The initial release rate (within 5 days) of the prepared microsphere thrombin was more than 20% faster than that of Example 1, and the drug release within 5 days reached 62%, and the drug release in the later period was significantly reduced.

[0092] The ratio of the equilibrium swelling volume of the prepared microspheres in physiological saline to that when flowing out in microfluidics was 1.41.

[0093] The prepared microspheres can withstand a compression deformation of 31%.

[0094] Without adding polyaspartic acid, the molecular chain density in the microspheres is reduced, making them easier to swell and the mechanical properties are greatly reduced. At the same time, due to the reduction of amino and carboxyl groups, the adsorption of phospholipids in the oil phase on the microsphere surface in the microfluidic output is reduced, thereby reducing the adsorption of rapamycin.

[0095] Comparative Example 4 Comparative Example 4 is compared with Example 1. In the preparation process a, polyaspartic acid and water-soluble dialdehyde chitosan are not added, and the other processes are completely the same.

[0096] The particle size of the prepared microspheres is 120-240 μm.

[0097] After the prepared microspheres were sprayed with the rapamycin composite solution, rapamycin could not form a continuous phase on the surface of the microspheres, and very little rapamycin was adsorbed on the surface.

[0098] The prepared microspheres began to degrade significantly under vascular physiological conditions after 12 days, and the microspheres began to deform.

[0099] The initial release rate of the prepared microsphere thrombin was significantly faster than that of Example 1, and more than 80% of the drug was released within 5 days.

[0100] The ratio of the equilibrium swelling volume of the prepared microspheres in physiological saline to that when flowing out in microfluidics was 1.46.

[0101] The prepared microspheres can withstand a compression deformation of 22%.

[0102] In addition to the effect of polyaspartic acid, the absence of water-soluble dialdehyde chitosan further weakened the cross-linking of the microspheres, making the microspheres more easily swollen and significantly reducing their ability to lock internal thrombin.

[0103] Comparative Example 5 Comparative Example 5 is compared with Example 1. In preparation process c, oxalic acid is not added, and the pH value is about 7; meanwhile, in preparation process d, alkali solution is not used for adjustment, and other processes are the same.

[0104] The prepared microspheres have poor formability and are easy to clog the chip in microfluidics; the particle size distribution of the prepared microspheres is wide, with the particle size ranging from 100-350 μm.

[0105] The prepared microspheres began to degrade significantly under vascular physiological conditions after 10 days, and the microspheres began to deform.

[0106] The initial release rate of thrombin from the prepared microspheres was significantly faster than that in Example 1.

[0107] The ratio of the equilibrium swelling volume of the prepared microspheres in physiological saline to that when flowing out in microfluidics was 1.84, and the microspheres were easily deformed.

[0108] The prepared microspheres can withstand a compression deformation of 34%.

[0109] pH adjustment will greatly affect the rate and process of cross-linking and have a significant impact on the properties of microspheres.

Claims

1. A biodegradable embolic microsphere with coagulation function, the preparation process of which is as follows: a: dissolving a certain amount of sodium alginate, water-soluble protein, thrombin, and water-soluble dialdehyde polysaccharide macromolecules in water to prepare an aqueous phase prepolymer solution; b: Using low viscosity oil mixed with lecithin as the oil phase; c: before adding to the microfluidics, the pH value of the aqueous prepolymer solution is adjusted to between 5 and 6.5 using a weak acid; d: The microspheres are obtained by outputting through microfluidic technology, and the flow rates of the water phase and the oil phase are controlled to control the size of the spheres; the outflowing microspheres are collected with a calcium chloride aqueous solution as a collecting liquid, and a weak alkaline solution is added to adjust the microsphere collecting liquid to neutrality, and the collecting liquid is continuously stirred at 100-200 rpm for 1-2 hours; f: After filtering out the microspheres, spraying the rapamycin composite solution on the surface of the microspheres with a nano-scale atomization spray device; g: After spraying, place the microspheres in normal saline and store at 0-4°C; Its characteristics are also: The mass concentration of sodium alginate in the aqueous prepolymer solution is between 3-6%, the mass concentration of water-soluble dialdehyde polysaccharide macromolecules is between 2-4.5%, and the volume concentration of thrombin is between 30-60 mg / ml; The mass concentration of phospholipids in the oil phase is between 2-4%; The mass concentration of the collected solution calcium chloride aqueous solution is between 2-4%.

2. The biodegradable embolic microsphere with coagulation function according to claim 1, characterized in that: The low-viscosity oil is one of ethyl acetate, hexane, liquid paraffin, and dimethyl silicone oil. After adding lecithin, an ultrasonic oscillation device is used to oscillate for 5-10 minutes to achieve homogenization.

3. The biodegradable embolic microsphere with coagulation function according to claim 1, characterized in that: The lecithin includes one of refined egg yolk lecithin, refined soybean lecithin and distearoyl lecithin.

4. The biodegradable embolic microsphere with coagulation function according to claim 1, characterized in that: The water-soluble protein is a water-soluble protein containing amino groups, including one of polyaspartic acid, polyglutamic acid and ε-polylysine.

5. The biodegradable embolic microsphere with coagulation function according to claim 1, characterized in that: The rapamycin composite solution uses 10% by mass DMSO / water solution as solvent, in which rapamycin, surfactant and mannitol are dissolved, wherein the concentration of rapamycin is between 1-4 mg / ml, the mass concentration of the surfactant is between 1-2%, and the mass concentration of mannitol is between 0.01-0.03%.

6. The biodegradable embolic microsphere with coagulation function according to claim 1, characterized in that: In microfluidics, the flow rate of the oil phase is 20-80 μL / min, and the flow rate of the water phase is 2-8 μL / min.

7. The biodegradable embolic microsphere with coagulation function according to claim 1, characterized in that: The water-soluble dialdehyde polysaccharide macromolecule is a polysaccharide with a dialdehyde structure, including one of starch, sodium alginate, xanthan gum, pullulan, dextran, chitosan and carrageenan, and has a molecular weight between 1000-8000.

8. The biodegradable embolic microsphere with coagulation function according to claim 1, characterized in that: The particle size of the microspheres is between 50-800 μm.

9. The biodegradable embolic microsphere with coagulation function according to claim 1, characterized in that: The rapamycin can achieve transfer to the embolized blood vessels within 2 hours of embolization.

10. The biodegradable embolic microsphere with coagulation function according to claim 1, characterized in that: The microspheres began to degrade between 16-24 days under vascular physiological conditions.

Citation Information

Cited By

  • Gel microsphere with core-shell structure and preparation method thereof

    CN121288003A